The glucagon component stimulates hepatic lipid metabolism, explaining superior liver fat reductions compared to GLP-1 or GLP-1/GIP monotherapies
Semaglutide also lowered cardiovascular risk in patients with diabetes (7)
Researchers surveyed nearly 2,000 people taking these medications, and patterns are starting to emerge. Over 70% of users reported eating less junk food, including packaged snacks, sugary drinks, frozen meals, and fast food
We adjust dosage as needed to ensure comfort and effectiveness
STEP2 and related trials in adults with type 2 diabetes and overweight/obesity demonstrated somewhat smaller absolute weight reductions (e.g., ~9.6% vs 3.4% at 68 weeks
Diagnosis was confirmed by the National Institutes of Health criteria for NF1 (Fig